31results about How to "Reduce the degree of edema" patented technology

The invention provides tissue-engineered corneal endothelium constructed in vitro and a preparation method thereof. The preparation method comprises the following steps: preparation of an ultrathin acellular porcine corneal posterior matrix; culture; induction of human multi-potent stem cells; construction of the tissue-engineered corneal endothelium; etc. According to the invention, the ultrathin acellular porcine corneal posterior matrix containing the Descemet's membrane is prepared and human multi-potent stem cell-derived corneal endothelial cells are cooperatively used for in-vitro construction of the tissue-engineered corneal endothelium; so problems in sources of cornea donors are overcome, and the problem that tissue-engineered corneas are too thick for clinical treatment is overcome.

The invention relates to a sterile zinc-based montmorillonite Band-Aid as well as a preparation method and an application thereof. The Band-Aid comprises base cloth, an inner pad and a bonding part, wherein a medicament is attached to the inner pad. The Band-Aid is characterized in that the medicament contains zinc-based montmorillonite. Free zinc ions and montmorillonite can be dissociated from the used zinc-based montmorillonite, the medicament side of the Band-Aid is pasted to a skin wound, and the montmorillonite dissociated from the zinc-based montmorillonite of the Band-Aid can form gel after encountering blood, so that bleeding is stopped quickly; the formed gel can be used as a protection layer on the surface and the periphery of the wound to prevent external bacteria from invading; the zinc ions dissociated from the zinc-based montmorillonite have antibacterial and anti-inflammatory effects and has astringent and healing effects on damaged skin.

The invention relates to compound montmorillonite lysozyme powder for treating skin ulcer, a preparation method and application thereof. The compound montmorillonite lysozyme powder is prepared from the following raw materials in parts by weight: 50-120 parts of montmorillonite, 5-10 parts of lysozyme, and 20-50 parts of hydroxy propyl cellulose. According to the invention, the montmorillonite and the lysozyme are used as the effective components and the pharmaceutic adjuvant of the compound montmorillonite lysozyme powder disclosed by the invention; and the compound montmorillonite lysozyme powder is prepared into a drug through the processes, such as a montmorillonite dry heat sterilization process, a lysozyme ultraviolet sterilization process and a hydroxy propyl cellulose ethylene oxide process. The invention further provides application of the preparation in preparation of a drug for treating skin ulcer. Due to drug delivery for skin external use, the compound montmorillonite lysozyme powder has better effects on skin ulcer in different periods.

The invention discloses a pharmaceutical composition for treating acute lung injury and belongs to the technical field of biopharmaceutical industry. The pharmaceutical composition comprises the following main components in parts by weight: 20-25 parts of puerarin, 0.2-0.4 part of verapamil, 1-2 parts of ulinastatin, 0.6-0.8 part of an NE inhibitor, 0.3-0.6 part of a salviae miltiorrhizae water extract and 0.4-0.8 part of glutamine. The invention provides the pharmaceutical composition for treating acute lung injury. By means of matched use of puerarin and verapamil, the pharmaceutical composition can effectively treat acute lung injury and inhibit rise of content of blood serum TNF-alpha, alleviate PMN infiltration, eliminate free radicals and alleviate the extent of lung tissue edema, and has an effective protecting action on acute lung injury; and moreover, the oxygenation index of arterial partial pressure of oxygen is obviously increased, and the respiratory function of a patient is improved. The pharmaceutical composition disclosed by the invention not only can treat acute lung injury effectively, but also plays a maintaining role on lungs, and is convenient to use and low in cost.

The invention provides a diseased limb edema prevention and elimination device, an auxiliary movement system and a working method, and relates to the field of medical instruments. The diseased limb edema prevention and elimination device comprises a flexible sleeve with an electric heating mechanism; the sleeve is matched with a support; the support is rotationally matched with a winding drum parallel to an outer wall generatrix of the sleeve; the winding drum and the sleeve are jointly matched with a binding belt; one end of the binding belt is fixed to the outer side face of the sleeve, andthe other end of the binding belt is wound around the sleeve and then wound around the winding drum; and the winding drum is used for tightening or loosening the part, wound around the winding drum, of the binding belt through rotation. The binding belt applies pressure to an affected limb or reduces the pressure applied to the affected limb through the sleeve by tightening or loosening the part,wound around the winding drum, of the binding belt; the affected limb is subjected to hot compress through an electric heating mechanism, so that the body temperature of the edema position of the affected limb is improved, and detumescence of the affected limb is promoted; and the binding belt is arranged to pressurize the affected limb when the affected limb is subjected to edema preliminarily, and the edema degree is reduced through external pressure, so that continuous expansion of the edema position is effectively prevented, and the detumescence recovery period is shortened.

The invention relates to the application of tilorone in preparing a medicine for reducing hemorrhagic stroke cerebral edema. Experiments show that the tilorone remarkably upregulates an IFN-related gene in mouse brain. In a collagenase-induced cerebral hemorrhage model, the tilorone obviously reduces the cerebral edema degree of a model mouse. Therefore, the types of application diseases of the tilorone are further enlarged, and new medicine selection is also provided for preventing and treating the cerebral edema of hemorrhagic stroke patients.

The invention discloses compound montmorillonite lysozyme ointment for treating skin ulcers and a preparation method and application thereof. The ointment is made of, by mass, 50-120 parts of montmorillonite, 5-10 parts of lysozyme, 5-10 parts of polyethylene glycol 4000, 2-6 parts of glycerin, 3-8 parts of sorbitol and 80-164 parts of sterile water. According to the compound montmorillonite lysozyme ointment, montmorillonite and lysozyme are used as the effective constituents of the ointment and are made to the medicament with pharmaceutic adjuvant through the technologies of dissolution, high-temperature sterilization, filter membrane filtration sterilization, low-speed homogenizing, high-speed homogenizing, stirring, cooling, sterile filling and the like. The invention further provides application of the preparations for preparing medicines for treating skin ulcers. External used medicines are delivered for skin, and the ointment has good effects for treatment of skin ulcers at different times.

The invention relates to a spiro compound used for treating cerebral apoplexy. Shown by a test result, the compound can remarkably improve nerve injury caused by ischemia reperfusion of rice undergoing ischemia reperfusion, can remarkably reduce the cerebral infarction percentage and relieve the edema degree of brain tissue of the rice and can lower the water content. Therefore, the compound has an excellent treatment effect for cerebral apoplexy, especially cerebral arterial thrombosis.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a phlegm-eliminating and dampness-eliminating pharmaceutical composition and application thereof. The phlegm-eliminating and dampness-eliminating pharmaceutical composition is prepared from the following raw material components in parts by mass: 15-30 parts of fructus trichosanthis, 9-30 parts of allium macrostemon, 9-15 parts of rhizoma pinellinae praeparata, 9-30 parts of codonopsis pilosula, 6-15 parts of curcuma zedoary and 2-6 parts of coptis chinensis. A coronary heart disease damp syndrome mouse model experiment shows that the phlegm eliminating and dampness eliminating formula can remarkably improve ST segment and T wave pressure of a coronary heart disease damp syndrome mouse, inhibit myocardial hypertrophy of the coronary heart disease damp syndrome mouse, reduce leakage of myocardial injury zymogram of CK-MB, cTnT, LDH and oxLDL, protect myocardial tissue of ischemia injury, reduce cardiac enlargement caused by isoprenaline, reduce cardiomyopathy change caused by isoprenaline treatment, keep more myocardial cell structures normal, reduce inflammatory cell infiltration, stabilize membrane structures and reduce edema degree, thereby having a better treatment effect on ischemic heart disease or angina pectoris.

The invention relates to the technical field of medicines, in particular to novel application of nicotinic glycoside (kaempferol-3-O-rutinoside) or analogues thereof in preparation of medicines for preventing and treating traumatic brain injury. The compound has an obvious protection effect on traumatic brain injury of rats, can obviously relieve the encephaledema degree of the rats after injury, improves the behavioral functions after injury, and can improve movement and cognitive impairment and the like within a period of time after injury. Therefore, the compounds represented by nicotinic glycoside can be used for preparing medicines for preventing and treating traumatic brain injury.

The invention relates to an application of zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder in preparation of medicines for healing skin wounds. The zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder is prepared from the following raw materials in parts by mass: 5-10 parts of zinc-based montmorillonite and 8-12 parts of calcium-based montmorillonite. According to the invention, zinc-based montmorillonite and calcium-based montmorillonite are used as effective ingredients of the medicament provided by the invention, and the effective ingredients are combined with pharmaceutical auxiliary materials to be prepared into the medicament through the processes of high-temperature dry heat sterilization, mixing, sterile sub-packaging and the like. Through skin external administration, the medicament can be used for quickly coagulating blood and arresting bleeding as well as preventing wound infection, has anti-bacterial and anti-inflammatory effects, and has converging and healing effects on the injured skin.

The invention discloses application of a calycosin derivative in preparing a medicine for treating cerebral ischemia reperfusion injury. Through experiments, an applicant discovers that the calycosin derivative can up-regulate expression levels of ERalpha and GPR30, and can be more beneficial to reducing a neurological function score, reducing a cerebral infarction volume and reducing a cerebral oedema degree compared with calycosin; the calycosin derivative can dose-dependently up-regulate an ERK1/2 and Akt phosphorylation level, and plays a role in protecting an ischemia reperfusion injury nerve cell. The calycosin derivative has a structure as shown in the formula (I) which is shown in the description.